Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Neopharmed Gentili
Deal Size : $264.0 million
Deal Type : Divestment
BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed
Details : Under the agreement, BioCryst sell will its European Orladeyo (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, business to Neopharmed Gentili.
Product Name : Orladeyo
Product Type : Other Small Molecule
Upfront Cash : $250.0 million
June 27, 2025
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Neopharmed Gentili
Deal Size : $264.0 million
Deal Type : Divestment
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCryst's NDA for ORLADEYO Oral Granules in HAE Kids Accepted by FDA
Details : Orladeyo (berotralstat), plasma kallikrein inhbitor, which is being evaluated for the treatment in pediatric patients with hereditary angioedema aged 2 to <11 years.
Product Name : Orladeyo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2025
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCryst Announces FDA Approval of Orladeyo (berotralstat), First Oral, Once-daily Therapy
Details : Orladeyo (berotralstat) is a first oral, once-daily therapy which is approved for the treatment of patients with hereditary angioedema.
Product Name : Orladeyo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable